Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Rheos Medicines

Request full access

A biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease

Cambridge, United StatesFounded 2018Biotech & Life Sciences

About Rheos Medicines

Rheos Medicines is pioneering the field of immunometabolism to develop innovative, precision medicines aimed at treating patients with severe immune-mediated diseases and cancer. The company leverages cutting-edge research to translate insights in immunometabolism into novel therapeutic solutions. Rheos Medicines primarily serves patients suffering from complex immune system disorders and various forms of cancer, operating within the biopharmaceutical market. The business model is centered around research and development, with revenue generated through the commercialization of its proprietary treatments and potential collaborations with other pharmaceutical companies. The company's approach is highly specialized, focusing on the intersection of immunology and metabolism to create targeted therapies that address unmet medical needs.

Source: Dealroom company data

At a glance

Status
Closed
Employees
29
Open positions
None listed
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Mar 2018 $60M $240M Third Rock Ventures —
SPINOUTOther financing Jan 2018 $0 — Max Planck Innovation · Yale University · Max Planck Society —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Rheos Medicines website traffic

Latest recorded traffic for Rheos Medicines is 490 monthly website visits, down 55.5% over the last three months. Rheos Medicines's team grew 16% over the past year.

Latest monthly visits490 3-month web change-55.5% 1-year team growth+16%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Rheos Medicines in the Cambridge ecosystem

Live from Dealroom

The Rheos Medicines office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Other known investors3 additional known investors

  • Max Planck Innovation
  • Max Planck Society
  • Yale University
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Rheos Medicines on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Rheos Medicines’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.